[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Other Articles
June 16, 1962


JAMA. 1962;180(11):966. doi:10.1001/jama.1962.03050240062014

Herpetic keratitis, alias dendritic keratitis, has been one of ophthalmology's biggest problems. In this country it is not only the most common cause of corneal ulceration, but it is also the most common cause of blindness resulting from corneal scarring and secondary infection. Treatment heretofore by cauterization and debridement has been radical and not satisfactory.

It now appears that an antimetabolite 5-iodo-2'-deoxyuridine (IDU) is a potential inhibitor of herpes simplex and an effective therapeutic agent for keratitis caused by this virus. In the May issue of the Archives of Ophthalmology, Kaufman and collaborators1 report a well-controlled study of the treatment of experimental herpetic keratitis and cite preliminary observations on patients with this disease. The results have been most gratifying.

IDU is an effective antibiotic for the herpes simplex virus when used topically and may be effective for other virus infections as well. The idea of using thymine analogues to

Kaufman, H. E.; Nesburn, A. B.; and Maloney, E. D.:  Treatment of Herpes Simplex Keratitis ,  Arch Ophthal 67:583-591 ( (May) ) 1962.Crossref
Thompson, R. L., et al.:  The Effects of Antagonists on the Multiplication of Vaccina Virus in Vitro ,  Science 110:454, 1949.Crossref